CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is saf ...
Phase 1
Durham, North Carolina, United States and 12 other locations
purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate...
Phase 1
Durham, North Carolina, United States and 6 other locations
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potentia ...
Phase 1
Durham, North Carolina, United States and 24 other locations
ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate...
Phase 2
Durham, North Carolina, United States and 2 other locations
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also de...
Chapel Hill, North Carolina, United States and 7 other locations
This study will enroll prostate cancer patients with an unfavorable intermediate- or high-risk diagnosis. The purpose of this study ...
Phase 2
Durham, North Carolina, United States
Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate...
Phase 3
Chapel Hill, North Carolina, United States and 42 other locations
inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficie...
Phase 2
Durham, North Carolina, United States and 12 other locations
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stim...
Phase 3
Durham, North Carolina, United States and 72 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Durham, North Carolina, United States and 131 other locations
Clinical trials
Research sites
Resources
Legal